Charles Schwab Investment Management Inc. Lowers Holdings in Omeros Co. (NASDAQ:OMER)

Charles Schwab Investment Management Inc. lowered its stake in shares of Omeros Co. (NASDAQ:OMER) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 475,526 shares of the biopharmaceutical company’s stock after selling 9,509 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Omeros were worth $4,698,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of OMER. US Bancorp DE acquired a new stake in Omeros during the fourth quarter worth about $81,000. China Universal Asset Management Co. Ltd. purchased a new stake in Omeros in the 4th quarter worth approximately $121,000. BNP Paribas Financial Markets grew its stake in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. Seros Financial LLC purchased a new position in shares of Omeros during the 4th quarter valued at approximately $159,000. Finally, New York State Common Retirement Fund lifted its stake in shares of Omeros by 245.4% in the 4th quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 12,300 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

OMER has been the topic of several analyst reports. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Friday, March 21st. Finally, StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Performance

NASDAQ:OMER opened at $9.16 on Wednesday. The company has a fifty day moving average of $8.72 and a two-hundred day moving average of $7.44. Omeros Co. has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The stock has a market capitalization of $530.82 million, a PE ratio of -3.97 and a beta of 2.03.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.